Navigation Links
Omeros Reports Outcome of Phase 3 Trials of OMS103HP
Date:3/31/2011

day's news.  To access the live call by telephone, please dial 866-788-0545 (United States and Canada) or 857-350-1683 (International). The passcode is 43644952.  In addition, the live conference call will be webcast and can be accessed on the "Events" page of the Company's website at http://www.omeros.com.

A replay of the webcast will be available on the Company's website for one week.  A telephone replay will also be available for one week starting at 5:30 p.m. Eastern time today, which can be accessed by dialing 888-286-8010 (United States and Canada) or 617-801-6888 (International) and entering passcode 82323682.

About Omeros Corporation

Omeros is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, bleeding and disorders of the central nervous system. The Company's most clinically advanced product candidates are derived from its proprietary PharmacoSurgery™ platform designed to improve clinical outcomes of patients undergoing a wide range of surgical and medical procedures. Omeros has five ongoing clinical development programs, including three from its PharmacoSurgery™ platform and two from its addiction franchise. Omeros may also have the near-term capability, through its GPCR program, to add a large number of new drug targets and their corresponding compounds to the market. Behind its clinical candidates and GPCR platform, Omeros is building a diverse pipeline of protein and small-molecule preclinical programs targeting inflammation, bleeding and central nervous system disorders.

Forward-looking Statements

This press release contains forward-looking statements as defined within the Private Securities Litigation Reform Act of 1995, which are subject to the "safe harbor" created by those sections. These statements include, but are not limited to, statements regarding the
'/>"/>

SOURCE Omeros Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Omeros Announces Initiation of Patient Enrollment in OMS201 Phase 1 Study
2. Omeros Announces Publication of Clinical Results for OMS103HP in Arthroscopy: The Journal of Arthroscopic and Related Surgery
3. Omeros Announces Patient Enrollment in Phase 1/Phase 2 Study of OMS302
4. Omeros and The Parkinsons Institute and Clinical Center Enter into a Collaboration Agreement to Evaluate Novel Target for the Treatment of Movement Disorders
5. Omeros Receives $3.1 Million Milestone Payment from The Stanley Medical Research Institute for Schizophrenia Program
6. Omeros Prices Initial Public Offering of Common Stock at $10.00 Per Share
7. Omeros Announces National Institute on Drug Abuses Support for Phase 2 Clinical Study in Addiction Program
8. Omeros Corporation to Host Third Quarter 2009 Financial Results Conference Call on November 19
9. Daniel K. Spiegelman Elected to Board of Directors of Omeros
10. Omeros Reports Additional Phase 2 Data Showing Multiple Clinical Benefits In Patients Undergoing Meniscectomy Surgery
11. Omeros Selects Clinical Candidate for MASP-2 Program With Potential Applicability to Multiple Inflammatory Disorders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2014)... BLUE BELL, Pa. , Aug. 26, 2014 ... PRA Health Sciences, largest office worldwide. PRA, a leading global Contract ... and Fort Washington locations into ... . The new office opened this week and marks the ... an exciting time for us at PRA," said Harris Koffer ...
(Date:8/26/2014)... , Aug. 26, 2014 Biomedical Research ... has been named to the prestigious 2014 Inc. 500 ... honored to be included on this prestigious list and ... Chris Jacob , Biomedical Research Laboratories, CEO. "Today,s ... further serves to validate the hard work and talent ...
(Date:8/26/2014)... , Aug. 26, 2014 ... of the "Global Veterinary Diagnostics Market 2014-2018" ... Veterinary diagnostics include various tests, which are used ... livestock producers, and biomedical researchers are mainly availing ... testing (Deoxyribonucleic Acid/Ribonucleic Acid testing), immunodiagnostics, clinical chemistry, ...
Breaking Medicine Technology:PRA Health Sciences Expands in Pennsylvania 2Biomedical Research Laboratories Named to Inc. 500 List of America's Fastest-Growing Companies 2Global Veterinary Diagnostics Market 2014-2018: Key Vendors are Abaxis, Heska, IDEXX Laboratories, Mindray Medical, VCA Antech and Zoetis 2Global Veterinary Diagnostics Market 2014-2018: Key Vendors are Abaxis, Heska, IDEXX Laboratories, Mindray Medical, VCA Antech and Zoetis 3
(Date:8/27/2014)... Chicago, Illinois (PRWEB) August 27, 2014 ... integration project in the US with Buzz™ Digital O.R. ... The foundation of all 13 new operating rooms will ... control and management. This integrative system supports planning, navigation, ... is an advanced fusion of intuitive software and hardware ...
(Date:8/27/2014)... August 27, 2014 SCOTT Sports ... Park, Utah’s first indoor mountain bike and BMX park. ... park-style bikes in both adult and youth sizes for the ... operated a distribution warehouse in Ogden, Utah, recently moved its ... , “We are proud to be a partner with the ...
(Date:8/27/2014)... Steven Reinberg HealthDay Reporter ... hormone used to reduce the need for blood transfusions might ... suggests. Synthetic erythropoietin (EPO), which stimulates red blood cell ... preterm birth, said lead researcher Dr. Petra Huppi, a professor ... in Switzerland. "The real test of whether EPO protects ...
(Date:8/27/2014)... microGUNE, the Co-operative Research Centre into Microtechnologies, ... to generate innovative solutions based on microtechnologies ... industry and life sciences, among others. IK4-Ikerlan, ... are collaborating with CIC microGUNE on this ... by the Etortek 2013-2014 programme of the ...
(Date:8/27/2014)... water and oil and are persistent towards aggressive ... characteristics have made the fluorochemicals useful in numerous ... paper and board. , The problem with fluorochemicals ... and accumulate in both humans and the environment. ... effects, such as cancer, increased cholesterol and a ...
Breaking Medicine News(10 mins):Health News:Aspirus Wausau Hospital Announces First Large Scale Digital Operating Room Integration Project in the US 2Health News:Aspirus Wausau Hospital Announces First Large Scale Digital Operating Room Integration Project in the US 3Health News:SCOTT Sports to Sponsor Wasatch Indoor Bike Park 2Health News:Hormone Might Help Preemies' Brains 2Health News:Hormone Might Help Preemies' Brains 3Health News:Microtechnologies for driving forward mobility and human health 2Health News:Leading scientists call for a stop to non-essential use of fluorochemicals 2Health News:Leading scientists call for a stop to non-essential use of fluorochemicals 3
... many aren,t getting preventive treatments , , THURSDAY, Jan. ... patients in hospitals worldwide risk developing dangerous blood ... receiving treatments that could prevent the condition, a ... long been recognized to be one of the ...
... NEW YORK, Jan. 31 QED International Associates, ... 20 underlying,indexes for the HealthShares(TM) Exchange-Traded Funds, today ... Monday February 4, 2008,BioMerieux Worldwide (Euronext: BIM) will ... European Medical Products and Devices Index., Companies ...
... But analysis calls gap between these and lower-tier facilities ... admitted to the top-rated hospitals in the United States ... than patients admitted to other hospitals in the country, ... an independent health-care ratings organization, the analysis of 27 ...
... Set for February 29, 2008, PALO ALTO, ... JAZZ ) announced today that the U.S. Food ... submission of the,response by Solvay Pharmaceuticals, Inc. to ... maleate) Extended-Release Capsules. The,FDA has notified Solvay Pharmaceuticals ...
... N.J., Jan. 31 Medarex, Inc.,(Nasdaq: MEDX ) ... the,Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device,Conference at ... event will be,webcast live and will be available in ... http://www.medarex.com . An archived edition of the,presentation will ...
... Jan. 31 Acura,Pharmaceuticals, Inc. (OTC Bulletin Board: ... Market(R) has approved the Company,s application to,list its ... The,Company,s common stock will commence trading on NASDAQ ... "We are pleased to join the growing ...
Cached Medicine News:Health News:Hospital Patients' Blood Clot Risk High 2Health News:Hospital Patients' Blood Clot Risk High 3Health News:Top-Rated Hospitals Continue to Deliver Better Care 2Health News:Jazz Pharmaceuticals, Inc. Announces Submission of Complete Response to FDA Approvable Letter for LUVOX(R) CR 2Health News:Medarex to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference 2Health News:Acura Pharmaceuticals, Inc. Announces Approval to List Shares on NASDAQ and Effective Feb. 4, 2008 a New Trading Symbol: ACUR 2
... Graham-Field has been developing diverse ... 58 years. Our medical-surgical products ... for innovation, quality and customer ... include the Labtron® line of ...
Kit Nebulizer Small Volume Medication W/Pediatric Mask Mouthpiece 7FT O 2 Tubing...
... Small Volume Medication Mouthpiece 7FT O 2 ... advanced jet design for fast treatment times , ... a tighter distribution (higher percentage of respirable particles) ... AirLife™ brand Misty Max 10™ disposable nebulizers deliver ...
... Products, ,Westmed designs, manufacturers and markets ... Respiratory professionals. Our mission is to design ... ability to deliver quality medical care while ... , ,Our web site is designed ...
Medicine Products: